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Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is considered a
modelofpurevasculardementia(VD)becauseitoccursinyoungadultsunlikelytohaveconcomitantageandAlzheimer’sDisease-
(AD-) related pathology. CSF levels of β-amyloid 1-42 (Aβ42), total tau protein (t-tau), and phosphorylated tau-protein (p-tau),
well accepted biomarkers of AD, were evaluated in 10 CADASIL patients, 22 AD patients, and 17 healthy age-matched subjects.
Innotest β-amyloid 1-42, Innotest hTAU-Ag, and Innotest Phospho-tau 181p sandwich enzyme-linked immunoassay were used
to determine CSF biomarkers levels. A case-control statistical analysis was carried out. CSF Aβ42 levels were signiﬁcantly lower in
CADASIL patients and considerable overlap with AD whereas t-tau and p-tau levels were normal and signiﬁcantly diﬀerent with
respect to AD. A signiﬁcant altered CSF biomarkers proﬁle in a pure VD supports the use of CSF Aβ42, t-tau, and p-tau levels in
the diﬀerential diagnosis of VD and AD.
1.Introduction
Despite the increased use of widely accepted diagnostic
criteria over the last 1-2 decades, the diﬀerential diagnosis
between Alzheimer disease (AD) and vascular dementia
(VD), the most common causes of dementia in the elderly,
is not always easy in the clinical practice. Many cognitively
impaired patients, with a progressive history of classical
cortical dementia, show diﬀerent degrees of concomitant
vascular lesions [1]. Vascular comorbidity may be present
in 30%–60% of AD patients [2], and, conversely, AD
pathology may be present in 40%–80% of VD patients
[3], thus hindering diagnosis accuracy. Further, because the
prevalence of both AD and VD increases with age, the
coexistence of AD and VD in the elderly patients would also
be expected to occur.
Cerebral Autosomal Dominant Arteriopathy with Sub-
cortical Infarcts and Leukoencephalopathy (CADASIL) is an
inherited microvascular disease associated with a wide range
ofsymptomsincludingmigraine,mooddisorders,andrecur-
rent subcortical TIA/strokes [4, 5]. Two thirds of CADASIL
patients early develop subcortical dementia, usually in the
fourth-ﬁfth decades of life [6]. Due to its monogenic nature
and occurrence in young adults, CADASIL is considered a
usefulmodelofVD,inwhomage-andAD-relatedpathology
unlikely to coexist [7].
Beta-amyloid1-42 (Aβ42), total tau (t-tau), and phospho-
tau (p-tau) proteins, indices of amyloid deposition, axonal
damage, or tangle formation respectively, have been sug-
gested as biomarkers for the diagnosis in dementia disorders
[8]. The CSF proﬁle of these proteins in patients with AD is
characterized by decreased Aβ42 and increased t-tau and p-
tau levels [9, 10]. On the contrary in VD, studies on these
CSF biomarkers showed conﬂicting results: t-tau levels have
been reported to be increased [11–13], normal [14, 15]o r
intermediate [16, 17], but in any case much lower than2 International Journal of Alzheimer’s Disease
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moderately decreased [18] or signiﬁcantly overlapping with
AD [19]. Few works deal with p-tau reporting either normal
[20] or increased CSF levels [21]i nV D .
Since previous studies showed contradictory results in
VD, we evaluated CSF biomarkers in CADASIL, a young-
onset monogenic disease which oﬀers a unique opportunity
to deﬁne CSF biomarkers proﬁle in a pure VD. For this
purpose we assessed CSF Aβ42, t-tau, and p-tau levels in
ten CADASIL patients, comparing the results with those
obtained for twenty-two AD patients and seventeen control
subjects.
2. Patientsand Methods
Afterobtaininginformedconsent,wemeasuredCSFAβ42,t-
tau, and p-tau levels in CADASIL patients, AD patients, and
control subjects.
CADASIL group included ten genetically conﬁrmed
patients (age range 49–66 years), followed in our department
and already described in previous works by our group
[22, 23]. Patients have been enrolled in a study on CSF
biomarkers for the early diagnosis of dementia approved
by local ethical committee. Detailed demographic data and
molecular features of CADASIL patients are reported in
Table 1.
The AD group consists of twenty-two patients with
probable AD (age range 58–74 years) diagnosed in our
department according to the NIN-CDS-ADRDA criteria
[24]. AD patients with more than one cardiovascular risk
factor and patient with even 1-2 white matter lacunes were
excluded. None of the AD patients was under treatment for
dementia at the time of lumbar puncture.
The control group included seventeen age-matched
subjects with polyneuropathy and without signs of cognitive
decline or central nervous system lesions.
Overall cognitive performance was evaluated in all
three groups by Mini-Mental-State Examination (MMSE).
MMSE scores below 26 indicate the presence of cognitive
impairment.
CSF was obtained by standard procedures, collected in
polypropylene tubes and immediately centrifuged. All blood
contamination-free samples were stored at −80
◦C until
assay, CSF levels of Aβ42, t-tau, and p-tau were determined
by sensitive sandwich enzyme-linked immunoassay ELISA:
Innotest β-amyloid 1-42, Innotest hTAU-Ag, and Innotest
Phospho-tau 181p (speciﬁc for tau proteins phosphorylated
at threonine 181) (Innogenetics, Ghent, Belgium). All deter-
minations were done in duplicate.
3.StatisticalAnalysis
The nonparametric test of Kruskal-Wallis was used instead
of the Analysis of Variance (ANOVA) because Levene’s test
rejected the hypothesis of equality of sample variances.
Pairwise group comparisons were then made using the
nonparametric test of Mann-Whitney with Bonferroni cor-
rection of type-I error probability.
A statistical signiﬁcance level of 95% (type-I error
probability, P, less than .05) was considered for all tests.
Statistical analysis was executed with the statistical pack-
age SPSS 10.
4. Results
Descriptive statistics of clinical features and CSF levels of
Aβ42, t-tau, and p-tau, including median and interquartile
distance (25th to 75th percentile), for CADASIL, Alzheimer
patients, and controls are reported at the bottom of Table 1.
Figures 1(a)–1(c) supply a box plot representation of CSF
grouped data.
Aβ42. CSF Aβ42 levels were signiﬁcantly lower both
in CADASIL and in Alzheimer patients than in controls
(Kruskal-Wallis and Bonferroni-corrected Mann-Whitney
tests, P<. 05). However CSF Aβ42 levels in CADASIL did
not signiﬁcantly diﬀer from those in Alzheimer (Bonferroni-
corrected Mann-Whitney test, P>. 05). Group diﬀerences
are illustrated in Figure 1(a): grey boxes, which represent
group interquartile intervals (25th to 75th percentiles),
overlap only for CADASIL and Alzheimer data.
t-tau and p-tau. Statistically signiﬁcant higher values
were found in Alzheimer with respect to both control
and CADASIL subjects (Kruskal-Wallis and Bonferroni-
corrected Mann-Whitney tests, P<. 05), while these last
two groups are not result statistically diﬀerent (Bonferroni-
correctedMann-Whitneytest,P>. 05).Figures1(b)and1(c)
show clear diﬀerences.
5. Discussion
Many studies evaluated changes in CSF Aβ42 and tau
protein in prodromal stages of AD or in other types of
dementia. Tau is an axonal protein that binds to tubulin in
microtubules, promoting their assembly and stability [25].
Elevated CSF levels of t-tau and p-tau have been interpreted
as indicators of ongoing neuronal and axonal degeneration
and/or the presence of neuroﬁbrillary tangles in the brain
[26]. β-amyloid (Aβ) peptides are a major component of
amyloid plaques deposited in the brain of patients with
diﬀerent neurodegenerative diseases. Decreased CSF Aβ42
levels have been ascribed to accumulation in senile plaques
[27]. However alternative mechanisms, such as formation
of a CSF chaperon complex with high-aﬃnity binding and
epitope masking of Aβ42, have also been reported [28].
LowCSFAβ42,hight-tau,andp-taulevelsarethetypical
pattern in AD, whereas in VD, until now, results on CSF
biomarkers are conﬂicting [17, 18].
Ethnic and methodological diﬀerences may account for
this discrepancy, as high assay variability is present amongst
laboratories using the same ELISA test [29]. However VD
is a heterogeneous entity and diﬀerent authors may study
diﬀerent subpopulations of patients, and it is diﬃcult to
assessthespeciﬁcityofCSFbiomarkersproﬁle.Furthermore,
as many patients with VD also show cholinergic lesions of
aging and AD, possible overlaps of vascular pathology and
A Dc a n n o tb er u l e do u t[ 30–32].International Journal of Alzheimer’s Disease 3
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Figure 1: Box plots of CADASIL and Alzheimer patients and control subjects. They include median (horizontal line within box),
interquartile interval, that is, 25th to 75th percentile (grey box) and range of variation (whiskers): (a) t-tau data, (b) p-tau data, and (c)
A β1-42 data.
In a previous study we reported signiﬁcantly lower CSF
Aβ42 levels in CADASIL patients than in controls whereas
CSF t-tau and p-tau did not diﬀer between the two groups
[33].
In the present study the CSF biomarkers levels of the
same CADASIL patients have been compared with those of
AD patients showing an altered proﬁle in CADASIL patients:
Aβ42 levels were markedly decreased and considerably
overlapped with AD, whereas t-tau and p-tau levels were
normal and signiﬁcantly diﬀerent with respect to AD.
Recent studies on CSF biomarkers proﬁle in sporadic VD
showed a clear decrease of Aβ42 levels [19]. The mechanism
of decreased CSF Aβ42 levels in cerebrovascular disease is
unclear however the presence of these features in sporadic
VD and in patients with a young-onset vascular disorder
like CADASIL suggests that altered CSF Aβ42 levels may
be related to subcortical vascular lesions and independent
from an age- and AD-related pathology. Recently, a link
between white matter lesions and low CSF Aβ42 has also
been reported [34]. Moreover, the signiﬁcant overlap of CSF
Aβ42 levels in a pure VD and AD suggests to rule out any
possible correlation between decreased CSF Aβ42 levels and
accumulation in senile plaques and strengthens the most
recent hypotheses about alternative mechanisms of Aβ42
reduction [28].
Normalt-tauandp-tauCSFlevelswefoundinCADASIL
contrast with the majority of the results of other groups
on t-tau and p-tau values in sporadic VD. However, in the
latter group of patients the possible presence of additional
neuropathological changes associated with age and AD
cannot be ruled out. Since CADASIL represents a model of
pure VD, we can argue that t-tau and p-tau CSF levels in
CADASIL patients closely reﬂect a pathological condition
almost exclusively due to cerebrovascular features. We can
thus suggest that CSF neurochemical phenotypes, especially
t-tau and p-tau levels, suﬃciently discriminate between AD
and VD.
In conclusion, although our little sample size can reduce
the statistical power of our results, signiﬁcant diﬀerences in
CSF biomarkers proﬁle between pure VD, AD, and controls
were found. These data support the use of CSF Aβ42, t-tau,
and p-tau levels in the diﬀerential diagnosis of VD and AD.International Journal of Alzheimer’s Disease 5
In any case, this study represents a preliminary investiga-
tion whose statistical results should be conﬁrmed by further
examinations on larger data samples.
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